Mindera Finds $12M For Psoriasis Analysis

San Diego-based Mindera, a startup developing a system that predicts patient response to psoriasis treatments, has raised $12M in a Series A-2 financing, according to the company. The funding came from Mountain Gro, up Partners, Rockmont Investments, and Scientific Health Development. Mindera said that the funding will go towards commercialization of its products, plus continued development. The company says its platform uses a simple patch that extracts biomarkers from the skin in minutes, allowing for rapid and painless extraction of RNA, which is analyzed by proprietary machine learning algorithms to predict the appropriate psoriasis biologic drug for a patient prior to therapeutic selection and treatment.